BOOTHBAY FUND MANAGEMENT, LLC - XENON PHARMACEUTICALS INC ownership

XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 82 filers reported holding XENON PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
BOOTHBAY FUND MANAGEMENT, LLC ownership history of XENON PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$384,346
-9.2%
9,983
-15.6%
0.01%
-11.1%
Q1 2023$423,217
-9.2%
11,8250.0%0.01%
-18.2%
Q4 2022$466,260
+9.2%
11,8250.0%0.01%0.0%
Q3 2022$427,000
-46.6%
11,825
-55.0%
0.01%
-47.6%
Q2 2022$800,000
+7.5%
26,306
+8.1%
0.02%
+23.5%
Q1 2022$744,000
+29.6%
24,326
+32.4%
0.02%
+21.4%
Q4 2021$574,000
-70.9%
18,376
-85.7%
0.01%
-74.5%
Q3 2021$1,970,000
-8.8%
128,924
+11.1%
0.06%
-20.3%
Q2 2021$2,161,000
+32.9%
116,057
+27.8%
0.07%
+13.1%
Q1 2021$1,626,000
+148.6%
90,816
+113.6%
0.06%
+154.2%
Q4 2020$654,000
+61.9%
42,513
+16.4%
0.02%0.0%
Q3 2020$404,000
-27.9%
36,518
-18.3%
0.02%
-36.8%
Q2 2020$560,000
-24.0%
44,685
-31.2%
0.04%
-37.7%
Q1 2020$737,000
+10.2%
64,989
+27.4%
0.06%
+5.2%
Q4 2019$669,000
+45.4%
51,0070.0%0.06%
+38.1%
Q3 2019$460,000
-9.8%
51,007
-1.5%
0.04%
-8.7%
Q2 2019$510,000
-32.3%
51,772
-30.2%
0.05%
-37.0%
Q1 2019$753,000
+243.8%
74,162
+113.8%
0.07%
+128.1%
Q4 2018$219,000
-13.8%
34,682
+79.9%
0.03%
+28.0%
Q3 2018$254,000
-21.8%
19,275
-45.4%
0.02%
-10.7%
Q2 2018$325,00035,3190.03%
Other shareholders
XENON PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Ghost Tree Capital, LLC 790,000$12,071,0003.53%
GREAT POINT PARTNERS LLC 700,000$10,696,0002.49%
COMMODORE CAPITAL LP 579,432$8,854,0002.33%
ACUTA CAPITAL PARTNERS, LLC 417,409$6,378,0002.25%
DAFNA Capital Management LLC 406,535$6,212,0001.65%
Tri Locum Partners LP 264,134$4,036,0001.60%
Parkman Healthcare Partners LLC 311,207$4,755,0001.20%
Ghost Tree Capital, LLC 250,000$3,820,0001.12%
Nan Fung Group Holdings Ltd 197,880$3,024,0000.97%
BVF INC/IL 1,571,778$24,017,0000.94%
View complete list of XENON PHARMACEUTICALS INC shareholders